Which has preferable earnings & valuation, AVLN or TWST?

Avalyn Pharma has higher earnings, but lower revenue than Twist Bioscience. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Avalyn Pharma N/A N/A N/A N/A N/A Twist Bioscience $376.57M 16.51 -$77.67M -$1.33 N/A

Does the media prefer AVLN or TWST?

In the previous week, Twist Bioscience had 10 more articles in the media than Avalyn Pharma. MarketBeat recorded 13 mentions for Twist Bioscience and 3 mentions for Avalyn Pharma. Avalyn Pharma's average media sentiment score of 0.82 beat Twist Bioscience's score of 0.13 indicating that Avalyn Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avalyn Pharma 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Twist Bioscience 4 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings and valuation, CGON or AVLN?

Avalyn Pharma has lower revenue, but higher earnings than CG Oncology. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CG Oncology $4.04M 1,571.01 -$160.99M -$2.33 N/A Avalyn Pharma N/A N/A N/A N/A N/A

Is CGON or AVLN more profitable?

Avalyn Pharma's return on equity of 0.00% beat CG Oncology's return on equity. Company Net Margins Return on Equity Return on Assets CG Oncology N/A -23.33% -22.24% Avalyn Pharma N/A N/A N/A

Does the media prefer CGON or AVLN?

In the previous week, CG Oncology had 3 more articles in the media than Avalyn Pharma. MarketBeat recorded 6 mentions for CG Oncology and 3 mentions for Avalyn Pharma. Avalyn Pharma's average media sentiment score of 0.82 beat CG Oncology's score of 0.09 indicating that Avalyn Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CG Oncology 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Avalyn Pharma 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, CRSP or AVLN?

Avalyn Pharma has lower revenue, but higher earnings than CRISPR Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CRISPR Therapeutics $3.51M 1,509.13 -$581.60M -$6.22 N/A Avalyn Pharma N/A N/A N/A N/A N/A

Does the media favor CRSP or AVLN?

In the previous week, CRISPR Therapeutics had 2 more articles in the media than Avalyn Pharma. MarketBeat recorded 5 mentions for CRISPR Therapeutics and 3 mentions for Avalyn Pharma. Avalyn Pharma's average media sentiment score of 0.82 beat CRISPR Therapeutics' score of 0.64 indicating that Avalyn Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CRISPR Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Avalyn Pharma 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, LEGN or AVLN?

Avalyn Pharma has lower revenue, but higher earnings than Legend Biotech. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Legend Biotech $1.03B 5.18 -$296.80M -$0.68 N/A Avalyn Pharma N/A N/A N/A N/A N/A

Does the media refer more to LEGN or AVLN?

In the previous week, Legend Biotech and Legend Biotech both had 3 articles in the media. Avalyn Pharma's average media sentiment score of 0.82 beat Legend Biotech's score of 0.63 indicating that Avalyn Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Legend Biotech 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Avalyn Pharma 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, AVLN or AMRX?

Amneal Pharmaceuticals has higher revenue and earnings than Avalyn Pharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Avalyn Pharma N/A N/A N/A N/A N/A Amneal Pharmaceuticals $3.02B 1.82 $72.06M $0.38 45.34

Does the media refer more to AVLN or AMRX?

In the previous week, Amneal Pharmaceuticals had 2 more articles in the media than Avalyn Pharma. MarketBeat recorded 5 mentions for Amneal Pharmaceuticals and 3 mentions for Avalyn Pharma. Avalyn Pharma's average media sentiment score of 0.82 beat Amneal Pharmaceuticals' score of 0.60 indicating that Avalyn Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avalyn Pharma 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amneal Pharmaceuticals 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Avalyn Pharma (AVLN) Competitors

$30.71 0.00 (0.00%)

As of 06/26/2026 04:00 PM Eastern

Compare

AVLN vs. TWST, CGON, CRSP, LEGN, and AMRX

Should you buy Avalyn Pharma stock or one of its competitors? MarketBeat compares Avalyn Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Avalyn Pharma include Twist Bioscience (TWST), CG Oncology (CGON), CRISPR Therapeutics (CRSP), Legend Biotech (LEGN), and Amneal Pharmaceuticals (AMRX). These companies are all part of the "pharmaceutical products" industry.

How does Avalyn Pharma compare to Twist Bioscience?

Avalyn Pharma (NASDAQ:AVLN) and Twist Bioscience (NASDAQ:TWST) are both pharmaceutical products companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, media sentiment, analyst recommendations, institutional ownership and risk.

In the previous week, Twist Bioscience had 10 more articles in the media than Avalyn Pharma. MarketBeat recorded 13 mentions for Twist Bioscience and 3 mentions for Avalyn Pharma. Avalyn Pharma's average media sentiment score of 0.82 beat Twist Bioscience's score of 0.13 indicating that Avalyn Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avalyn Pharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Twist Bioscience	4 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Avalyn Pharma has higher earnings, but lower revenue than Twist Bioscience.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalyn Pharma	N/A	N/A	N/A	N/A	N/A
Twist Bioscience	$376.57M	16.51	-$77.67M	-$1.33	N/A

Avalyn Pharma currently has a consensus target price of $59.00, indicating a potential upside of 92.12%. Twist Bioscience has a consensus target price of $74.60, indicating a potential downside of 25.28%. Given Avalyn Pharma's stronger consensus rating and higher possible upside, equities research analysts clearly believe Avalyn Pharma is more favorable than Twist Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalyn Pharma	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.20
Twist Bioscience	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

Avalyn Pharma has a net margin of 0.00% compared to Twist Bioscience's net margin of -19.85%. Avalyn Pharma's return on equity of 0.00% beat Twist Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalyn Pharma	N/A	N/A	N/A
Twist Bioscience	-19.85%	-26.73%	-19.15%

Summary

Avalyn Pharma beats Twist Bioscience on 7 of the 10 factors compared between the two stocks.

How does Avalyn Pharma compare to CG Oncology?

CG Oncology (NASDAQ:CGON) and Avalyn Pharma (NASDAQ:AVLN) are both pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, dividends, profitability, valuation, earnings, risk and institutional ownership.

26.6% of CG Oncology shares are held by institutional investors. 4.8% of CG Oncology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

CG Oncology presently has a consensus price target of $81.73, indicating a potential upside of 13.57%. Avalyn Pharma has a consensus price target of $59.00, indicating a potential upside of 92.12%. Given Avalyn Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Avalyn Pharma is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CG Oncology	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Avalyn Pharma	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.20

Avalyn Pharma has lower revenue, but higher earnings than CG Oncology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CG Oncology	$4.04M	1,571.01	-$160.99M	-$2.33	N/A
Avalyn Pharma	N/A	N/A	N/A	N/A	N/A

In the previous week, CG Oncology had 3 more articles in the media than Avalyn Pharma. MarketBeat recorded 6 mentions for CG Oncology and 3 mentions for Avalyn Pharma. Avalyn Pharma's average media sentiment score of 0.82 beat CG Oncology's score of 0.09 indicating that Avalyn Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CG Oncology	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Avalyn Pharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Avalyn Pharma's return on equity of 0.00% beat CG Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CG Oncology	N/A	-23.33%	-22.24%
Avalyn Pharma	N/A	N/A	N/A

Summary

Avalyn Pharma beats CG Oncology on 6 of the 11 factors compared between the two stocks.

How does Avalyn Pharma compare to CRISPR Therapeutics?

CRISPR Therapeutics (NASDAQ:CRSP) and Avalyn Pharma (NASDAQ:AVLN) are both pharmaceutical products companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, media sentiment, earnings and dividends.

Avalyn Pharma has lower revenue, but higher earnings than CRISPR Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CRISPR Therapeutics	$3.51M	1,509.13	-$581.60M	-$6.22	N/A
Avalyn Pharma	N/A	N/A	N/A	N/A	N/A

In the previous week, CRISPR Therapeutics had 2 more articles in the media than Avalyn Pharma. MarketBeat recorded 5 mentions for CRISPR Therapeutics and 3 mentions for Avalyn Pharma. Avalyn Pharma's average media sentiment score of 0.82 beat CRISPR Therapeutics' score of 0.64 indicating that Avalyn Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CRISPR Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Avalyn Pharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Avalyn Pharma has a net margin of 0.00% compared to CRISPR Therapeutics' net margin of -13,856.54%. Avalyn Pharma's return on equity of 0.00% beat CRISPR Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-13,856.54%	-25.66%	-20.39%
Avalyn Pharma	N/A	N/A	N/A

CRISPR Therapeutics currently has a consensus price target of $67.78, suggesting a potential upside of 23.41%. Avalyn Pharma has a consensus price target of $59.00, suggesting a potential upside of 92.12%. Given Avalyn Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Avalyn Pharma is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	1 Sell rating(s)	7 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.58
Avalyn Pharma	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.20

69.2% of CRISPR Therapeutics shares are held by institutional investors. 4.1% of CRISPR Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Avalyn Pharma beats CRISPR Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Avalyn Pharma compare to Legend Biotech?

Legend Biotech (NASDAQ:LEGN) and Avalyn Pharma (NASDAQ:AVLN) are both pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and earnings.

70.9% of Legend Biotech shares are held by institutional investors. 0.0% of Legend Biotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Legend Biotech presently has a consensus price target of $60.23, suggesting a potential upside of 109.94%. Avalyn Pharma has a consensus price target of $59.00, suggesting a potential upside of 92.12%. Given Legend Biotech's higher probable upside, equities research analysts clearly believe Legend Biotech is more favorable than Avalyn Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Legend Biotech	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.67
Avalyn Pharma	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.20

Avalyn Pharma has lower revenue, but higher earnings than Legend Biotech.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Legend Biotech	$1.03B	5.18	-$296.80M	-$0.68	N/A
Avalyn Pharma	N/A	N/A	N/A	N/A	N/A

In the previous week, Legend Biotech and Legend Biotech both had 3 articles in the media. Avalyn Pharma's average media sentiment score of 0.82 beat Legend Biotech's score of 0.63 indicating that Avalyn Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Legend Biotech	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Avalyn Pharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Avalyn Pharma has a net margin of 0.00% compared to Legend Biotech's net margin of -21.98%. Avalyn Pharma's return on equity of 0.00% beat Legend Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Legend Biotech	-21.98%	-24.92%	-14.87%
Avalyn Pharma	N/A	N/A	N/A

Summary

Avalyn Pharma beats Legend Biotech on 6 of the 11 factors compared between the two stocks.

How does Avalyn Pharma compare to Amneal Pharmaceuticals?

Avalyn Pharma (NASDAQ:AVLN) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership and profitability.

Amneal Pharmaceuticals has higher revenue and earnings than Avalyn Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalyn Pharma	N/A	N/A	N/A	N/A	N/A
Amneal Pharmaceuticals	$3.02B	1.82	$72.06M	$0.38	45.34

In the previous week, Amneal Pharmaceuticals had 2 more articles in the media than Avalyn Pharma. MarketBeat recorded 5 mentions for Amneal Pharmaceuticals and 3 mentions for Avalyn Pharma. Avalyn Pharma's average media sentiment score of 0.82 beat Amneal Pharmaceuticals' score of 0.60 indicating that Avalyn Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avalyn Pharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amneal Pharmaceuticals	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

31.8% of Amneal Pharmaceuticals shares are held by institutional investors. 17.3% of Amneal Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Avalyn Pharma currently has a consensus target price of $59.00, suggesting a potential upside of 92.12%. Amneal Pharmaceuticals has a consensus target price of $15.80, suggesting a potential downside of 8.30%. Given Avalyn Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Avalyn Pharma is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalyn Pharma	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.20
Amneal Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71

Amneal Pharmaceuticals has a net margin of 4.01% compared to Avalyn Pharma's net margin of 0.00%. Avalyn Pharma's return on equity of 0.00% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalyn Pharma	N/A	N/A	N/A
Amneal Pharmaceuticals	4.01%	-313.96%	7.49%

Summary

Amneal Pharmaceuticals beats Avalyn Pharma on 7 of the 12 factors compared between the two stocks.

Get Avalyn Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AVLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AVLN vs. The Competition

Export

Metric	Avalyn Pharma	Pharmaceutical Preparations Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$1.36B	$780.59M	$5.05B	$12.19B
Dividend Yield	N/A	4.84%	12.97%	6.11%
P/E Ratio	N/A	1.46	21.95	24.16
Price / Sales	N/A	118.69	160.43	102.83
Price / Cash	N/A	20.06	36.62	36.93
Price / Book	N/A	8.05	13.62	6.38
Net Income	N/A	-$3.83M	$113.19M	$337.00M
7 Day Performance	-6.85%	0.61%	-0.99%	-0.20%
1 Month Performance	6.71%	-0.72%	-3.43%	-1.40%
1 Year Performance	N/A	52.18%	11.94%	27.76%

Avalyn Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AVLN Avalyn Pharma	4.8567 of 5 stars	$30.71 flat	$59.00 +92.1%	N/A	$1.36B	N/A	N/A	51	High Trading Volume
TWST Twist Bioscience	1.3744 of 5 stars	$87.56 flat	$71.60 -18.2%	+177.9%	$5.45B	$376.57M	N/A	990	News Coverage Analyst Forecast Insider Trade High Trading Volume
CGON CG Oncology	2.0806 of 5 stars	$61.08 flat	$81.73 +33.8%	+177.3%	$5.39B	$4.04M	N/A	61	Positive News Insider Trade Gap Down High Trading Volume
CRSP CRISPR Therapeutics	2.5512 of 5 stars	$54.09 flat	$67.78 +25.3%	+15.6%	$5.22B	$3.51M	N/A	460	Analyst Upgrade
LEGN Legend Biotech	4.0323 of 5 stars	$27.93 flat	$60.23 +115.6%	-17.2%	$5.19B	$1.03B	N/A	2,965	Gap Down High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AVLN) was last updated on 6/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Avalyn Pharma (AVLN) Competitors

AVLN vs. TWST, CGON, CRSP, LEGN, and AMRX

How does Avalyn Pharma compare to Twist Bioscience?

Summary

How does Avalyn Pharma compare to CG Oncology?

Summary

How does Avalyn Pharma compare to CRISPR Therapeutics?

Summary

How does Avalyn Pharma compare to Legend Biotech?

Summary

How does Avalyn Pharma compare to Amneal Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVLN vs. The Competition

Avalyn Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Avalyn Pharma (AVLN) Competitors

AVLN vs. TWST, CGON, CRSP, LEGN, and AMRX

How does Avalyn Pharma compare to Twist Bioscience?

Does the media prefer AVLN or TWST?

Which has preferable earnings & valuation, AVLN or TWST?

Do analysts recommend AVLN or TWST?

Is AVLN or TWST more profitable?

Summary

How does Avalyn Pharma compare to CG Oncology?

Do insiders and institutionals have more ownership in CGON or AVLN?

Do analysts recommend CGON or AVLN?

Which has higher earnings and valuation, CGON or AVLN?

Does the media prefer CGON or AVLN?

Is CGON or AVLN more profitable?

Summary

How does Avalyn Pharma compare to CRISPR Therapeutics?

Which has stronger earnings and valuation, CRSP or AVLN?

Does the media favor CRSP or AVLN?

Is CRSP or AVLN more profitable?

Do analysts prefer CRSP or AVLN?

Do insiders & institutionals hold more shares of CRSP or AVLN?

Summary

How does Avalyn Pharma compare to Legend Biotech?

Do insiders & institutionals hold more shares of LEGN or AVLN?

Do analysts prefer LEGN or AVLN?

Which has stronger earnings & valuation, LEGN or AVLN?

Does the media refer more to LEGN or AVLN?

Is LEGN or AVLN more profitable?

Summary

How does Avalyn Pharma compare to Amneal Pharmaceuticals?

Which has better earnings & valuation, AVLN or AMRX?

Does the media refer more to AVLN or AMRX?

Do institutionals & insiders have more ownership in AVLN or AMRX?

Do analysts rate AVLN or AMRX?

Is AVLN or AMRX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVLN vs. The Competition

Avalyn Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools